EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cytochrome P450 2D6 *17 and *29 Allele Activity for Risperidone Metabolism: Advancing Precision Medicine Health Equity

Oyinlade Kehinde iD, Samuel E Vaughn iD, Ogochukwu Amaeze iD, Paul Toren, Brandon Retke iD, Akinyemi Oni-Orisan iD, Laura B Ramsey iD

Clinical Pharmacology & Therapeutics · 2025-11 · 118 (5) · 1152-1160

DOI: 10.1002/cpt.70012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 24.07.2025. Verfasst von Oyinlade Kehinde und 6 weiteren Autor:innen. Beteiligte Einrichtung: Child and Adolescent Mental Health Service Center (CAMHSC) Federal Neuro-Psychiatric Hospital, Lagos, Nigeria. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2D6, Risperidone, Precision Medicine, Antipsychotic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHGRI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CYP2D6 alleles with low frequency in Eurocentrically biased study populations are often excluded from pharmacogenetic investigation and consequently may have misassigned activity values. This health inequity may be contributing to imprecise dose predictions for CYP2D6‐metabolizing drugs. The objective of this study was to determine how sub‐Saharan African‐specific CYP2D6*17 and *29 alleles affect risperidone metabolism. To do this, we generated the largest real‐world cohort of risperidone users in an African study population for pharmacogenetic studies. Risperidone users ≤ 18 years old were recruited from the Federal Neuro‐Psychiatric Hospital. Health records were obtained by parent report and paper charts. CYP2D6 genotyping was performed for > 20 variants. Plasma concentrations of risperidone and 9‐hydroxyrisperidone were determined by liquid chromatography mass spectrometry. CYP2D6 activity was calculated based on the metabolic ratio 9‐hydroxyrisperidone:risperidone. Multivariable linear regression modeling was performed to determine the association between our alleles of interest and log‐transformed ratio‐defined CYP2D6 activity relative to star alleles with established activity values. Across 208 enrolled participants, CYP2D6 activity value for *17 was found to be twice that of normal function alleles, while *29 was comparable to no function alleles. These results contrast previous values assigned to *17 and *29 from guidelines, which are not based on evidence with risperidone, suggesting the possibility of substrate specificity for these alleles. Ultimately, our findings have the potential to improve risperidone prescribing, especially for patient groups with substantial sub‐Saharan African ancestry. Importantly, this work underscores the critical need to better understand the effects of ancestry‐specific alleles for achieving equitable pharmacotherapeutic health outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2D6RisperidonePrecision MedicineAntipsychotic AgentsHealth EquityHumansMaleAllelesFemalePaliperidone PalmitateAdolescentGenotypePharmacogeneticsBlack People

Substanzen

Cytochrome P-450 CYP2D6RisperidoneAntipsychotic AgentsPaliperidone Palmitate

Autor:innen und Institutionen

  • Child and Adolescent Mental Health Service Center (CAMHSC) Federal Neuro-Psychiatric Hospital, Lagos, Nigeria.
  • Division of Child & Adolescent Psychiatry, Department of Pediatrics, University of Cincinnati College of Medicine & Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Pharmaceutics, University of Washington, Seattle, Washington, USA.
  • Children's Mercy Research Institute, Children's Mercy Kansas City, Kansas City, Missouri, USA.
  • Department of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA.
  • Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Department of Pediatrics, University of Missouri Kansas City & Children's Mercy Kansas City, Kansas City, Missouri, USA.

ORCID-Profile: Oyinlade Kehinde, Samuel E Vaughn, Ogochukwu Amaeze, Brandon Retke, Akinyemi Oni-Orisan, Laura B Ramsey

Förderung

  • NHGRI NIH HHS

Zitieren

APA

Kehinde, O., Vaughn, S. E., Amaeze, O., Toren, P., Retke, B., Oni-Orisan, A., & Ramsey, L. B. (2025). Cytochrome P450 2D6 *17 and *29 Allele Activity for Risperidone Metabolism: Advancing Precision Medicine Health Equity. Clinical Pharmacology & Therapeutics, 118(5), 1152-1160. https://doi.org/10.1002/cpt.70012

Vancouver

Kehinde O, Vaughn SE, Amaeze O, Toren P, Retke B, Oni-Orisan A, et al. Cytochrome P450 2D6 *17 and *29 Allele Activity for Risperidone Metabolism: Advancing Precision Medicine Health Equity. Clinical Pharmacology & Therapeutics. 2025;118(5):1152-1160. doi:10.1002/cpt.70012

BibTeX
@article{Kehinde2025,
  author = {Kehinde, Oyinlade and Vaughn, Samuel E and Amaeze, Ogochukwu and Toren, Paul and Retke, Brandon and Oni-Orisan, Akinyemi and Ramsey, Laura B},
  title = {Cytochrome P450 2D6 *17 and *29 Allele Activity for Risperidone Metabolism: Advancing Precision Medicine Health Equity},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {118},
  number = {5},
  pages = {1152--1160},
  doi = {10.1002/cpt.70012}
}
Kostenlos starten →